Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4))

B. Eksteen; J. Heatherington; J. Oshiomogo; R. Panaccione; G. Kaplan; S. Ghosh

doi:10.1016/j.jhep.2016.10.020

Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4))

B. Eksteen
, J. Heatherington
, J. Oshiomogo
, R. Panaccione
, G. Kaplan
, S. Ghosh

Research output: Contribution to journal › Comment/Debate

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The abstract authors and presenters of PS124 – EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE submitted and presented at ILC 2016 have raised concerns that the source data in some cases are inconsistent and requires further evaluation to determine the true magnitude of effect. Hence given the potential impact of this study in PSC at the authors request this abstract, until such time the data can be more completely presented in manuscript form, is being retracted.

Original language	English
Pages (from-to)	254
Number of pages	1
Journal	Journal of Hepatology
Volume	66
Issue number	1
DOIs	https://doi.org/10.1016/j.jhep.2016.10.020
Publication status	Published - Jan 2017
Externally published	Yes

Access to Document

10.1016/j.jhep.2016.10.020

Fingerprint

Dive into the research topics of 'Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4))'. Together they form a unique fingerprint.

Cite this

Eksteen, B., Heatherington, J., Oshiomogo, J., Panaccione, R., Kaplan, G., & Ghosh, S. (2017). Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4)). Journal of Hepatology, 66(1), 254. https://doi.org/10.1016/j.jhep.2016.10.020

Eksteen, B. ; Heatherington, J. ; Oshiomogo, J. et al. / Retraction notice to : PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4)). In: Journal of Hepatology. 2017 ; Vol. 66, No. 1. pp. 254.

@article{476ddfb08b2a43d89dfea71082e795e0,

title = "Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4))",

abstract = "This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The abstract authors and presenters of PS124 – EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE submitted and presented at ILC 2016 have raised concerns that the source data in some cases are inconsistent and requires further evaluation to determine the true magnitude of effect. Hence given the potential impact of this study in PSC at the authors request this abstract, until such time the data can be more completely presented in manuscript form, is being retracted.",

author = "B. Eksteen and J. Heatherington and J. Oshiomogo and R. Panaccione and G. Kaplan and S. Ghosh",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2017",

month = jan,

doi = "10.1016/j.jhep.2016.10.020",

language = "English",

volume = "66",

pages = "254",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "1",

}

Eksteen, B, Heatherington, J, Oshiomogo, J, Panaccione, R, Kaplan, G & Ghosh, S 2017, 'Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4))', Journal of Hepatology, vol. 66, no. 1, pp. 254. https://doi.org/10.1016/j.jhep.2016.10.020

Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4)). / Eksteen, B.; Heatherington, J.; Oshiomogo, J. et al.
In: Journal of Hepatology, Vol. 66, No. 1, 01.2017, p. 254.

Research output: Contribution to journal › Comment/Debate

TY - JOUR

T1 - Retraction notice to

T2 - PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4))

AU - Eksteen, B.

AU - Heatherington, J.

AU - Oshiomogo, J.

AU - Panaccione, R.

AU - Kaplan, G.

AU - Ghosh, S.

PY - 2017/1

Y1 - 2017/1

N2 - This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The abstract authors and presenters of PS124 – EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE submitted and presented at ILC 2016 have raised concerns that the source data in some cases are inconsistent and requires further evaluation to determine the true magnitude of effect. Hence given the potential impact of this study in PSC at the authors request this abstract, until such time the data can be more completely presented in manuscript form, is being retracted.

AB - This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The abstract authors and presenters of PS124 – EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE submitted and presented at ILC 2016 have raised concerns that the source data in some cases are inconsistent and requires further evaluation to determine the true magnitude of effect. Hence given the potential impact of this study in PSC at the authors request this abstract, until such time the data can be more completely presented in manuscript form, is being retracted.

UR - https://www.scopus.com/pages/publications/85026268470

U2 - 10.1016/j.jhep.2016.10.020

DO - 10.1016/j.jhep.2016.10.020

M3 - Comment/Debate

C2 - 28042931

AN - SCOPUS:85026268470

SN - 0168-8278

VL - 66

SP - 254

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 1

ER -

Eksteen B, Heatherington J, Oshiomogo J, Panaccione R, Kaplan G, Ghosh S. Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease (Journal of Hepatology (2016) 64(2, Supplement) (S199) (S0168827816017074) (10.1016/S0168-8278(16)01707-4)). Journal of Hepatology. 2017 Jan;66(1):254. doi: 10.1016/j.jhep.2016.10.020

Abstract

Access to Document

Other files and links

Fingerprint

Cite this